HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

 What constitutes liver failure after transjugular intrahepatic portosystemic shunt creation? A proposed definition and grading system.

AbstractUNLABELLED:
 Background and rationale for the study. There is currently no definition of post-transjugular intrahepatic portosystemic shunt (TIPS) liver failure (PTLF), which constitutes a barrier to standardization of TIPS results reporting and limits the ability to compare liver failure incidence across clinical studies. Thisdescriptive study proposes and preliminarily tests the performance of a PTLF definition and grading system.
RESULTS:
PTLF was defined by ≥ 3-fold bilirubin and/or ≥ 2-fold INR elevation associated with clinical outcomes of prolonged hospitalization/increase in care level (grade 1), TIPS reduction or liver transplantation (grade 2), or death (grade 3) within 30-days of TIPS. PTLF incidence was 20% (grades 1, 2, 3: 10%, 3%, 8%) among 270 TIPS cases, and the scheme identified patients at increased risk for morbidity and mortality with a statistically significant difference in clinical outcomes between PTLF and non-PTLF groups (P<0.0001).
CONCLUSIONS:
In conclusion, the PTLF definition and classification scheme put forth distributes patients into unique risk groups. PTLF grading may thus be useful for standardization of TIPS results reporting.
AuthorsRon C Gaba, Janesh Lakhoo
JournalAnnals of hepatology (Ann Hepatol) 2016 Mar-Apr Vol. 15 Issue 2 Pg. 230-5 ISSN: 1665-2681 [Print] Mexico
PMID26845600 (Publication Type: Journal Article)
Chemical References
  • Bilirubin
Topics
  • Aged
  • Bilirubin (blood)
  • Blood Coagulation Disorders (blood)
  • Cohort Studies
  • Female
  • Hepatic Encephalopathy
  • Humans
  • Hypertension, Portal (surgery)
  • Incidence
  • International Normalized Ratio
  • Liver Failure (blood, classification, diagnosis, epidemiology)
  • Liver Transplantation
  • Male
  • Middle Aged
  • Portasystemic Shunt, Transjugular Intrahepatic
  • Postoperative Complications (blood, classification, diagnosis, epidemiology)
  • Retrospective Studies
  • Severity of Illness Index

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: